ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1375	National Cancer Institute	Html	en	Cancer Screening Overview (PDQ®)–Health Professional Version	Information about measuring the effectiveness of cancer screening tests and about weighing the strength of the evidence obtained from cancer screening research studies.	PDQ Screening 0.435302 cancer antigen 0.351044 cancer screening interventions 0.511292 advanced-stage pancreatic cancer 0.361147 cancer screening 0.938139 lung cancer screening 0.519031 new screening test 0.500274 cancer prevention 0.350991 Interval cancer events 0.364348 new screening modality 0.453389 IIIB–IV lung cancer 0.361117 prostate screening 0.417963 lung cancer rates 0.355466 prostate cancer treatment 0.3549 mammography screening 0.457867 screening program 0.415447 screening summaries 0.435473 disease-specific mortality 0.409334 cancer cases 0.346604 whole-body screening technologies 0.500642 lower cancer risk 0.359738 interval cancer rates 0.358328 colorectal cancer 0.351483 routine cancer screening 0.555956	recent screening 0.436851 false-negative screening test 0.511207 older screening modalities 0.448481 breast cancer 0.418358 cancer diagnosis 0.374736 prostate cancer screening 0.551218 actual cancer risk 0.422669 cancer screening tests 0.659235 randomized controlled trial 0.36573 prostate cancer mortality. 0.348853 false-positive screening results 0.509129 screening center 0.444606 fecal occult blood 0.356414 higher cancer risk 0.360321 cancer mortality. 0.353113 decision making 0.410621 all-cause mortality 0.362129 breast cancer overdetection 0.35093 routine screening mammographies 0.474709 randomized clinical trials 0.34952 Cancer Screening Trial 0.566983 invasive diagnostic procedures 0.355819 routine PSA screening 0.472621	CLICK HERE
1456	National Cancer Institute	Html	en	Vulvar Cancer Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of vulvar cancer.	lesion-type VIN grade 0.488217 radiation therapy arm 0.777718 vulvar surgical procedures 0.466679 sentinel node dissection 0.727156 Radiation Therapy section 0.586061 case series 0.468674 groin dissection study 0.616489 vulvar cancer 0.538035 positive sentinel nodes 0.479331 lymph node dissection 0.680638 sentinel node identification. 0.538816 invasive vulvar cancer 0.471336 vulvar cancer-related deaths 0.462293 radiation therapy issue 0.483522 clinically localized vulvar 0.482117 node dissection 0.932807 bloc inguinal node 0.506403 sentinel node dissections 0.642236 bilateral groin node 0.587002 Actuarial groin recurrence 0.544605 groin lymph 0.484094 pelvic node resection 0.498834 radical vulvectomy 0.489162 sentinel node 0.79935	high-grade vin 0.507503 bilateral dissection 0.465866 groin dissection arm 0.620835 invasive locoregional vulvar 0.48636 sentinel node procedures 0.539343 groin recurrence 0.545931 groin dissection 0.6467 femoral lymph node 0.521493 negative sentinel node 0.528158 negative sentinel nodes 0.475577 patients 0.605395 groin-node dissection 0.464 inguinal node dissection 0.663124 groin node dissection 0.784008 ipsilateral inguinal node 0.504912 pelvic radiation 0.458909 Node metastases 0.461128 groin node-positive disease 0.523738 groin radiation 0.532254 regional lymph nodes 0.463891 HPV 6/11-associated vulvar 0.461386 negative groin nodes 0.546977 systematic literature review 0.508112	CLICK HERE
1499	National Cancer Institute	Html	en	Paranasal Sinus and Nasal Cavity Cancer Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of paranasal sinus and nasal cavity cancer.	hemiparanasal sinus 0.501642 cure rates 0.493854 positive nodes 0.488668 standard treatment schedules 0.549584 Nodal involvement 0.497639 cancer deaths 0.490757 small percentage 0.485324 paranasal sinuses 0.76526 operable tumors 0.521562 PDQ cancer information 0.674275 (es). 0.507032 T1 mucosal carcinomas 0.579667 neck radiation therapy 0.604078 cancer information summary 0.645943 frequent type 0.494315 high doses 0.481624 Squamous cell carcinoma 0.582109 breast cancer prevention 0.543533 direct extension 0.48751 malignant degeneration 0.512598 advanced carcinomas 0.493525 ethmoid sinuses 0.558752 NCI’s PDQ 0.512104 NCI PDQ cancer 0.582736 paranasal sinus cancers 0.63814	radical surgery 0.487234 frontal sinuses 0.560784 radiation therapy 0.931486 low-grade benign tumor 0.581394 maxillary sinus 0.511122 locoregional recurrence accounts 0.563108 nasal vestibule 0.506572 Lymph nodes 0.492664 vital areas 0.483188 distant metastases 0.516432 bony confines 0.499241 malignant tumor 0.600994 PDQ documents 0.510902 early tumors 0.514544 radical radiation therapy 0.591316 advanced disease 0.493565 nasal cavity 0.593061 treatment volume 0.481814 local disease 0.484616 tumors 0.539577 stage III tumors 0.513203 neck cancer 0.495811 postoperative radiation therapy 0.591777 adjacent structures. 0.488857	CLICK HERE
1553	National Cancer Institute	Html	en	Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of childhood non-Hodgkin lymphoma.	cancer treatment 0.41722 Burkitt-like non-Hodgkin lymphoma 0.414505 panniculitis-like T-cell lymphoma 0.407586 mediastinal B-cell lymphoma 0.477834 type 0.421123 body 0.397298 childhood non-hodgkin lymphoma 0.888605 PDQ cancer information 0.389516 Non-Hodgkin Lymphoma Treatment 0.431482 clinical trial search 0.395907 B-cell non-Hodgkin lymphoma 0.444319 gamma-delta T-cell lymphoma 0.40789 clinical trials 0.596027 large cell lymphoma 0.576342 peripheral t-cell lymphoma 0.4403 clinical trial 0.545942 stem cell transplant 0.416614 Burkitt lymphoma 0.412037 anaplastic lymphoma kinase 0.405034 primary mediastinal b-cell 0.402494 diffuse large b-cell 0.419339 lymph nodes 0.504405 Pediatric-type follicular lymphoma 0.401311 large B-cell lymphoma 0.505692	radiation therapy 0.400696 childhood hodgkin lymphoma 0.422956 treatment 0.602592 Hodgkin Lymphoma Treatment 0.428936 cutaneous t-cell lymphoma 0.531706 cancer cells 0.482982 Burkitt-like lymphoma /leukemia 0.41493 HIV-related non-Hodgkin lymphoma 0.410943 certain gene changes 0.416336 Adult Non-Hodgkin Lymphoma 0.452762 recurrent lymphoblastic lymphoma 0.388804 lymphoblastic lymphoma 0.418163 follicular lymphoma 0.416701 combination chemotherapy 0.479578 non-hodgkin lymphoma 0.995932 bone marrow 0.469909 marginal zone lymphoma 0.455485 cells 0.53075 cancer clinical trials 0.407298 lymph node 0.390457 treatment options 0.51667 anaplastic large cell 0.523091 HIV-associated non-Hodgkin lymphoma 0.431952 cancer 0.673011	CLICK HERE
1559	National Cancer Institute	Html	en	Endometrial Cancer Screening (PDQ®)–Patient Version	Expert-reviewed information summary about tests used to detect or screen for endometrial cancer.	cancer treatment 0.561966 Pap test results 0.564545 ongoing clinical trials 0.564273 following PDQ summaries 0.605267 PDQ cancer information 0.713937 false-negative test result 0.559289 Uterine Sarcoma Treatment 0.562863 uterus 0.565825 Endometrial sampling 0.614718 clinical trials 0.686375 test result 0.59341 transvaginal ultrasound 0.592257 cancer information summary 0.653614 clinical trial 0.570758 test results 0.593938 breast cancer prevention 0.577475 false-positive test result 0.559048 latest published information 0.566054 PDQ® Screening 0.557798 NCI’s PDQ 0.572282 cancer symptoms 0.57367 NCI PDQ cancer 0.624163 tests 0.615659 black women 0.581998	PDQ Screening 0.598441 treatment 0.572654 cancer prevention 0.577647 screening tests 0.574176 cancer cells 0.559463 endometrial cancer screening 0.701539 Cancer Information Service 0.589993 Prevention Editorial Board 0.603972 treatment clinical trials 0.562297 National Cancer Institute 0.661886 endometrial cancer 0.979643 PDQ documents 0.56725 new treatment 0.567011 Cancer screening trials 0.628138 Cancer Care page 0.581539 PDQ database 0.570002 breast cancer 0.579583 abnormal vaginal bleeding 0.663193 non-polyposis colon cancer 0.588586 risk factor 0.558033 PDQ summary 0.615448 yearly screening 0.56313 cancer information summaries 0.594869 comprehensive cancer information 0.595413	CLICK HERE
1617	National Cancer Institute	Html	en	Chronic Myeloproliferative Neoplasms Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of chronic myeloproliferative neoplasms.	red blood cells 0.746761 chronic idiopathic myelofibrosis 0.40092 cancer treatment 0.416363 primary myelofibrosis 0.53957 PDQ cancer information 0.430215 bone marrow aspiration 0.385705 clinical trial search 0.421224 white blood cells 0.676519 chronic eosinophilic leukemia 0.451961 blood cells increases 0.444984 clinical trials 0.768861 chronic neutrophilic leukemia 0.40279 mature blood cells 0.434847 fewer blood cells 0.406923 cancer information summary 0.401424 clinical trial 0.500574 early signs 0.377313 patients 0.431687 blood cells 0.902472 blood vessels 0.37721 chronic myelogenous leukemia 0.406738 Treatment Editorial Board 0.377482 essential thrombocythemia 0.420345 treatment 0.55278 stored stem cells 0.37624	immature blood cells 0.399031 blood stem cell 0.37725 cancer cells 0.408902 -fighting blood cells 0.405086 lymphoid stem cell 0.374191 specific cancer cells 0.392312 chronic myeloproliferative neoplasms 0.69658 signs 0.38226 polycythemia vera 0.418683 patient 0.388228 treatment clinical trials 0.396123 blood stem cells 0.497004 National Cancer Institute 0.457233 routine blood test 0.45249 new treatment 0.393316 white blood cell 0.399685 extra blood cells 0.469808 bone marrow 0.605562 PDQ summary 0.382577 cancer clinical trials 0.425229 blood clots 0.392843 cancer 0.517448 information 0.439199 Myelogenous Leukemia Treatment 0.387746	CLICK HERE
1836	National Cancer Institute	Html	es	Tratamiento de la leucemia mieloide aguda y otras neoplasias mieloides malignas infantiles (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento de la leucemia mieloide aguda infantil, síndromes mielodisplásicos y otras neoplasias mieloproliferativas.	frecuencia mutaciones 0.438095 LMA familiares 0.551304 leucemia eritroidea aguda 0.449843 American Academy 0.418016 Leucemia aguda eritroidea 0.453243 gen runx1t1 0.417024 neoplasias mieloides 0.421266 transient leukemia 0.421355 Sin embargo 0.442991 gen crebbp 0.417273 LMA ayuda 0.492779 necesarias mutaciones 0.436351 leucemia mielomonocítica aguda 0.45265 Panmielosis aguda 0.424398 subtipo fab 0.419671 leucemias mieloides 0.437133 Leucemia basofílica aguda 0.453074 leucemia mielógena 0.434701 Children's Oncology Group 0.430324 gen etv6 0.41685 leucemia transitoria 0.433759 reordenamiento leucemia aguda 0.452795 Leucemia megacarioblástica aguda 0.453115 Smith MA 0.431884 Leucemia aguda mielomonocítica 0.453529	gen evi1 0.417889 leucemia promielocítica aguda 0.56535 Organización Mundial 0.42957 gen mll 0.697325 células madre 0.41719 leucemia aguda 0.953312 LMA M0 0.546818 leucemia linfoblástica aguda 0.491741 SAI Leucemia 0.451225 tipo ii 0.459931 gen runx1 0.418208 Pediatr Blood Cancer 0.433879 gen cbf-beta 0.418127 M0 LMA 0.495335 leucemia monocítica aguda 0.501087 fraterno presente leucemia 0.436812 linaje mieloide 0.448127 leucemias bifenotípicas mieloides 0.422616 leucemia megacariocítica aguda 0.525006 leucemia mieloblástica aguda 0.537614 BCR-ABL1 Leucemia aguda 0.451622 leucemia mieloide aguda 0.756372 linaje linfoide 0.423692 La traslocación 0.522981	CLICK HERE
2002	National Cancer Institute	Html	es	Tratamiento del feocromocitoma y paraganglioma (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del feocromocitoma y paraganglioma.	associated with 0.440801 paraganglioma hereditario sdhd 0.442898 Surg Oncol Clin 0.439027 Gimenez-Roqueplo AP 0.438768 Chatellier G 0.438739 patients with apparently 0.435891 with von hippel-lindau 0.426826 evaluation following resection 0.43956 gastric stromal sarcoma 0.435317 Carney JA 0.479643 hereditary paraganglioma 0.424404 gland scaled score 0.43937 Clin Proc 0.426209 effective treatment with 0.472522 secondary hypertension 0.431368 Neuroendocrine Neoplasias 0.453768 extra-adrenal paraganglioma 0.447147 von hippel-lindau 0.471522 feocromocitoma síndrome 0.499112 patients with 0.828258 Clin Endocrinol Metab 0.986823 Young WF Jr 0.474746 or secreting 0.439481 Servais A 0.436374 patients with metastatic 0.46137	Surg Pathol 0.438013 hypertension persistence after 0.484322 adrenal gland scaled 0.443509 Fofol I 0.439495 Feocromocitoma Opciones estándar 0.480462 Endocrinol Metab Clin 0.443246 feocromocitoma metastásico cirugía 0.494173 during pregnancy 0.424683 feocromocitoma-paraganglioma familiar tipo 0.517532 Long-term evaluation following 0.440068 endocrina múltiple tipo 0.439079 Pacak K 0.437715 Heerden JA 0.443555 with combination chemotherapy 0.426625 Intern Med 0.453092 autosomal dominant paraganglioma 0.427278 Clin Oncol 0.478285 extra suprarrenales surgen 0.434497 extra suprarrenales 0.652785 carney triad 0.424742 feocromocitoma regional cirugía 0.492979 parasimpáticos extra suprarrenales 0.431253 associated with sdhb 0.428378 familial paraganglioma 0.44151	CLICK HERE
2053	National Cancer Institute	Html	es	Vacunas contra los virus del papiloma humano	Una hoja informativa acerca de las vacunas contra los virus del papiloma humano (VPH) para prevenir infecciones con ciertos tipos de VPH, los cuales son la causa principal del cáncer de cuello del útero o cérvix.	HPV prophylactic vaccines 0.314226 hpv vaccine 0.332876 Lancet Oncology 0.308843 with preexisting infection 0.306342 Mortality Weekly Report 0.31501 bivalent hpv vaccination 0.314902 largo plazo 0.306588 Disease Control 0.307862 genital warts among 0.306064 clinical trial 0.315859 anal hpv 0.312394 Estados Unidos 0.376477 hpv vaccination 0.357231 Hariri S 0.317621 Rica Vaccine Trial 0.314539 PubMed Abstract 0.885463 human papillomavirus 0.614779 vacunas gardasil® 0.319024 Infectious Diseases 0.318629 quadrivalent hpv 0.312783 Chaturvedi AK 0.307922 BMC Infectious Diseases 0.305886 hpv infection 0.324228 Hildesheim A 0.314688 Feng Q 0.308321	among young 0.314298 papillomavirus acquisition 0.305662 United States 0.307989 alto riesgo 0.531462 Updated HPV Vaccination 0.328083 British Medical Journal 0.305646 HPV Vaccination Recommendations 0.328083 Costa Rica 0.313988 Immunization Practices 0.308391 Advisory Committee 0.307786 papillomavirus among 0.306019 infecciones persistentes.  gardasil 0.336098 9-valent human papillomavirus 0.32439 papillomavirus prophylactic vaccines 0.30978 Bocchini JA 0.307795 ¿Cuáles cánceres 0.312957 Hughes JP 0.308264 bivalent hpv 0.331056 cuello uterino 0.992097 Vaccine Safety Datalink 0.314052 genital hpv infection 0.315334 Cancer Institute 0.307587 New England Journal 0.348895 Petrosky E 0.307326	CLICK HERE
15738	National Cancer Institute	Html	en	Financial Toxicity and Cancer Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the risk of experiencing financial difficulty during cancer treatment.	adult cancer survivors 0.29753 cancer treatment 0.260149 study 0.333877 high out-of-pocket spending 0.29174 health insurance 0.332995 newly diagnosed cancer 0.254116 out-of-pocket cost burden 0.275794 financial hardship 0.814372 colorectal cancer patients 0.270243 colorectal cancer survivors 0.274934 economic burden 0.33821 higher out-of-pocket spending 0.308086 Support Care Cancer 0.263278 material financial hardship 0.310411 Cancer Care Outcomes 0.299421 high out-of-pocket costs 0.25691 health care 0.364957 out-of-pocket health care 0.305633 higher out-of-pocket costs 0.256873 high out-of-pocket burden 0.326935 State cancer patients 0.282656 cancer care 0.417219 personal financial burden 0.365783 lung cancer patients 0.262392	ongoing cancer care 0.28258 colorectal cancer 0.3351 cancer patients 0.489203 Clin Oncol 0.334879 comprehensive cancer center 0.290609 cancer-related financial burden 0.257868 cancer diagnosis 0.320181 later financial hardship 0.252008 Long-term financial burden 0.276409 financial distress 0.563858 out-of-pocket spending 0.410176 breast cancer survivors 0.328299 financial burden 0.630038 out-of-pocket costs 0.285058 greater financial burden 0.273818 financial toxicity 0.49873 cancer survivors 0.880073 advanced-stage cancer patients 0.289755 high financial burden 0.284717 cancer 0.949444 substantial financial hardship 0.256681 risk 0.255869 cancer history 0.289124	CLICK HERE